Cytori to Include Lupus Patients in Studies of Cell Therapy for Secondary Raynaud’s Phenomenon
Cytori Therapeutics will expand the scope of its Habeo Cell Therapy (ECCS-50) for secondary Raynaud’s phenomenon to include patients with systemic lupus erythematosus and other autoimmune conditions in addition to scleroderma patients. It made the decision after a pilot trial (NCT01813279) of the cell therapy helped 12 scleroderma patients…